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ABSTRACT: Many studies evaluating the effectiveness of coronary artery bypass graft surgery 
allude to the quality of life benefit resulting from surgery. However, no comprehensive 
empirical estimate of the absolute or relative magnitude of this benefit is currently 
available. This paper presents a data synthesis of the research literature on bypass 
surgery to derive such an estimate. It uses follow-up measures of the percent of patients 
who were angina-free within both the surgical and medical groups of 14 controlled 
trials to estimate the quality of life benefit following surgery. Results based on the 
longest reported follow-up period suggest that the chances are approximately 25 to 
40% greater that patients will be angina-free if they receive surgery rather than medical 
treatment. Estimates of benefit are about 15% less in randomized controlled trials 
compared to controlled trials that used a matching strategy. These results are unlikely 
to be affected by related factors such as the percentage of patients who crossover from 
the medical group to the surgical group or the specific method of calculating anginal 
relief used in this research report. However, differential patient selection may account 
for the observed design effect. 
KEY WORDS: quality-of-life, data synthesis, meta-analysis, coronary artery bypass graft surgery, an- 
gina, controlled clinical trials. 
The evaluat ion of medical  technologies often depends  on  assessment  of 
quali ty of life benefits  to pat ients  such as f reedom from pain, psychological  
well-being, and  physical mobili ty [1,2]. Quali ty of life may  also be an impor-  
tant  considerat ion for technologies initially thought  to be life preserving.  
Coronary  ar tery bypass  graft surgery  (CABGS) is a case in point  because the 
p rocedure  may  be r e c o m m e n d e d  to relieve the often debil i tat ing angina ac- 
company ing  coronary  hear t  disease. Randomized  trials have not  repor ted  a 
consis tent  benefi t  in improved  survival and  lower  mortal i ty for pat ients  re- 
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ceiving the surgery [3,4]. Furthermore, the recently completed Coronary Ar- 
tery Surgery Study (CASS) of patients with "mild" angina included a variety 
of quality of life measures (e.g., exercise test performance, employment status, 
recreational status) [5]. While no significant surgical benefits were found for 
mortality, survival, and myocardial infarction rates [6], many significant ben- 
efits on surgical patients' quality of life were found [5]. The assessment of 
this and other technologies poses a dilemma for the evaluator because most 
studies do not routinely include quality of life results using comparable mea- 
sures. 
A quality of life assessment based on the existing scientific literature must 
often rely on proxy variables or more indirect indicators. The most commonly 
reported indicator of quality of life reported in the CASS and other bypass 
studies has been the relief from angina pectoris, the often debilitating pain 
associated with coronary artery disease. CABGS has been presumed to pro- 
duce significant relief of angina since the first, uncontrolled studies were 
reported [7,8]. The National Institutes of Health [9] reflected this view in 
responding to the question, "What is known about the long-term quality of 
life after coronary artery surgery?" The NIH consensus statement noted, 
The symptom of angina pectoris is reported to be relieved in 80 to 90 percent 
of the patients undergoing surgery for chronic stable angina. 
From a technology assessment perspective, unfortunately, this statement 
is limited in two major ways. First, it does not quantify the degree to which 
patients could expect their angina to be relieved following an operation. Con- 
ceivably, a large majority of patients might have improved only slightly and 
still have satisfied the letter of this statement. Second, because two courses 
are open to most patients (surgical or medical treatment), it is impossible for 
a patient to assess the potential additional benefit involved in undergoing the 
operation compared to the advantage of staying on a medical regimen. As 
McPeek, Gilbert, and Mosteller [10] note for most surgical procedures, "The 
patient's quality of life after the recovery phase matters most in choosing the 
treatment." Should there be considerable relief from angina associated with 
medical therapy, the decision to choose surgery becomes even more difficult. 
An assessment of the quality of life benefit thus requires comparative data 
that also reflect the incidence of anginal relief in control groups of patients 
not undergoing surgery. Such information is especially critical because there 
are numerous instances in which a major, new surgical intervention was later 
shown to produce only placebo benefits in pain relief (e.g., gastric freezing, 
internal mammary artery ligation). A previous review by Buccino and Mc- 
Intosh [11] did cite evidence from controlled trials of CABGS pertaining to 
complete relief of chronic angina. However,  Buccino and McIntosh's review 
was based on just four studies, only two of which were randomized clinical 
trials (RCTs), and was restricted to examining the statistical significance be- 
tween surgical and medical groups. 
The primary purpose of the present research was to derive an estimate of 
the quality of life benefit for surgical patients in previous controlled trials of 
CABGS by aggregating the results from the individual studies published in 
the scientific literature. This study also illustrates both the potential and the 
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limitations in synthesizing data from published studies to assess an important 
benefit of most medical research technologies. 
The systematic examination of results of multiple clinical trials evaluating 
the same health intervention is a technique that has been endorsed [12] and 
utilized for some time [13]. Recently, quantititative procedures, such as meta- 
analysis, have been applied to cumulate the findings of similar studies [14-17]. 
These cumulation methods use the results from individual studies to derive 
a pooled measure of the average magnitude of treatment impact such as an 
effect size [15] or risk ratio [16]. Furthermore, the procedure allows the re- 
viewer to quantify the contribution of research design or methodology, which 
is typically impossible within an individual study [18]. 
METHODS 
Quality of Life Measure 
The outcome measure used in this synthesis was based on the percentage 
of patients in either a surgical or medical group of a given study who were 
reported to be angina-free at both entry into the study and the longest reported 
follow-up period. Choice of the percent of patients who were angina-free as 
an indicator of life quality was dictated primarily by the frequency with which 
it was reported in published studies. No other quality of life variable was 
cited as often. Patients classified as New York Heart Association Type I or as 
asymptomatic were considered to be angina-free. 
Selection of Studies 
Studies were selected from four sources. These included prior reviews 
[11,19], references from relevant articles, a MEDLARS U search from 1974-1981 
using coronary bypass surgery as the keyword, and the table of contents of 
major medical journals for the past several years. From these four sources 91 
studies were identified whose tire indicated that some version of CABGS had 
been tested. Of these 91 studies, 26 were controlled clinical trials that com- 
pared results in a surgical and a medical group. Of these 26 studies only 15 
reported results on relief of angina and these were examined more closely. 
Studies were included that had similar (within 2 months) follow-ups in sur- 
gical and medical groups. One of the potentially usable studies was excluded 
because the average follow-up periods for assessment of the percent of pa- 
tients who were angina-free in medical and surgical groups differed by 13 
months. No other exclusion criteria were employed. Thus, selected studies 
represent the total number of controlled clinical trials available in the period 
1970-1983 that had contrasted survival or death in groups of surgical and 
medical patients with coronary heart disease. 
The 14 trials included in this research (see Appendix) were comparable to 
the 12 excluded trials. Pertinent averages from the included and excluded 
trials were, respectively: follow-up times (30 months vs. 27 months), percent 
crossovers of medically treated patients to surgery (14% vs. 9%), year of 
publication (1977 for both included and excluded studies), distribution of the 
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vs. 15%, 26%, and 59%), and mortality difference between surgical and med- 
ical groups (12% vs. 7%). No statistical tests of the significance of the difference 
between these averages were conducted due to the small sample size and 
low statistical power of such tests. 
To reduce the likelihood that the same patients had been included in dif- 
ferent reports, those studies sharing the same authors were inspected. If study 
patients came from different medical centers, had mutually exclusive years 
of enrollment, were of different ages, or had different types of coronary 
disease, then studies were considered to include different patient groups. 
Five of the studies shared the same author, and it was not possible to establish 
whether the same patients were studied or the extent of the possible dupli- 
cation. However, no two of the studies had the same sample sizes or were 
simply follow-ups of earlier studies. Thus, it was assumed that no duplicate 
studies were present. 
Because a number of investigators have shown that research design is 
related to the magnitude of observed treatment benefit for CABGS [17,20], 
this research also examined results by design category. Two design categories 
were used: RCTs in which patients were reported to have been assigned to 
surgical or medical groups by a random process, or nonrandomized trials 
("quasiexperiments") [21] which created concurrent contruis using nor .an-  
dora assignment which involved matching patients with similar histories and 
other relevant characteristics. 
D a t a  C u m u l a t i o n  P r o c e d u r e  
The studies were coded independently by the authors for number of pa- 
tients, attrition, and relief of angina; all coding discrepancies were resolved. 
For each of the two groups in a study--surgery and medicine--a fraction was 
formed whose numerator was the number of patients who were angina-free 
and whose denominator was the total number of patients who were assigned 
to respective groups at the beginning of the study (see Table 1). Surgically 
assigned patients were not counted unless they actually received CABGS. 
This resulted in small changes in four of the 14 studies (31 of 390 surgical 
patients in the CASS study, 27 of 395 in the European study, 1 of 56 in Mathur 
and Guinn, and 1 of 22 in Berk et al.). These modified totals appear as n/grp 
in Table 1. 
Because the denominator for the follow-up calculations was based on orig- 
inal sample size at entry, estimates were not artifactually increased by the 
lack of availability of patients at follow-up, exclusions due to medical cross- 
overs, or the number of deaths. Moreover, this makes the data for each group 
comparable over time so that meaningful comparisons can be made. Entry 
percents could then be subtracted from follow-up percents within both the 
surgical and medical groups. Finally, the medical difference was subtracted 
from the surgical difference, yielding the relative benefit due to surgery. 
Sample sizes reflecting these rules have been indicated as n/grp for each of 
the studies in Table 1. 
To illustrate these calculations, in Table 1 of the recent CASS report, 22% 
of medical and 23% surgical patients had no chest pain at entry while the 
figures were 35% and 58%, respectively, of those still living at the end of 5 
years. Recalculating the entry result in the surgical group so that it represents 
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only those patients assigned to the surgical group actually receiving CABGS 
yields an adjusted figure of 25.1%. Follow-up results were recalculated in 
both groups to reflect the number of patients at entry (rather than the total 
number of surviving patients), thus producing figures of 23.3% (medical) and 
41.8% (surgical). The recalculated medical difference was 1.3% (23.3-22.0%) 
while the recalculated surgical difference was 16.7% (41.8-25.1%). Hence, the 
net benefit for surgery was 15.4% (16.7-1.3%). (The computational formula 
appears at the end of the Appendix.) Therefore, each study result represents 
the difference in degree of complete symptom relief between all surgical 
patients who received CABGS and all patients assigned to medical groups, 
including those who may have received surgery. 
Typically, one value was reported for the percent of patients who were 
angina-free and, unless stated otherwise, it was assumed that this result 
reflected the average follow-up period that was reported. If multiple figures 
were reported for varying lengths of follow-up, only data coinciding with the 
longest period of follow-up were coded. Thus, in the CASS example above, 
follow-up data from 1 and 3 years were also reported, but not included in 
this analysis. 
From these within-study results, the overall, average benefit was calculated 
by finding the arithmetic average of benefits found in each of the 14 individual 
studies. The average relative benefit was also calculated for each of two design 
categories composed of six RCTs and eight nonrandomized trials. 
RESULTS 
The average benefit due to surgery was 39.2% across the 14 studies used 
in this research (see Tables 1 and 2, line 1). That is, the incidence of surgical 
patients who were angina-free was 39.2% higher, on the average (p < 0.05, 
test for the difference between proportions), than the incidence of angina- 
free, medical patients. In no case was the percentage of patients who were 
angina-free in the medical group higher than the percentage of patients who 
were angina-free in the surgical group at the longest follow-up. 
When stratified by design, the average benefit due to surgery was 29.8% 
in the six RCTs and 46.2% in the eight nonrandomized trials. A Mann-Whitney 
nonparametric test indicated that this difference approached the usual cri- 
terion for statistical significance (z = 1.61, corrected for continuity, p < 0.06). 
An alternative parametric analysis of the follow-up results using a pooled or 
common odds ratio was also performed (as recommended by Yusuf et al. 
[22]). The odds ratios (and 95% confidence intervals) were 4.42 (3.50, 5.57) 
and 6.30 (4.91, 8.08) for RCTs and nonrandomized trials, respectively. It 
should be noted that the comparable Mantel-Haenszel average odds ratios 
were 4.89 and 9.03 with all ratios from the individual studies indicating a 
benefit for surgery. The former, average odds ratio, however, was nonhom- 
ogeneous indicating a consistent interaction favoring surgery. This result is 
consistent with previous findings based on mortality and survival outcomes 
in which nonrandomized trials also overestimated the benefit of surgery rel- 
ative to the estimates obtained in RCTs [17,20]. 
The present design effect (see Table 2, Line 1) resulted almost entirely from 
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surgical groups of nonrandomized trials (57.7%) as compared to the average 
entry vs. follow-up difference for the surgical groups in RCTs (42.8%). The 
medical group results were nearly the same for both types of trials. The 
average entry vs. follow-up difference was 11.5% for the medical groups in 
nonrandomized trials and 13.0% for the medical groups in the RCTs. 
As a check on the accuracy of these findings, results were recalculated 
aggregating the number of angina-free patients and the total sample size 
across all studies rather than averaging percents from individual studies. 
While such pooling is a more controversial aggregation method [23], it does 
permit studies to be weighted by their sample size. The results were consistent 
with those found by averaging percents across studies. The overall estimate 
of subjective benefit decreased from 39.2 to 27.3%, and the magnitude of the 
design effect dropped slightly from 16.4 to 12.1% (see Table 2, Line 2). 
DISCUSSION 
This study illustrates the potential for obtaining quality of life information 
from the existing scientific literature. It also provides an opportunity to ad- 
dress some of the methodological issues in the assessment of quality of life 
benefits and to discuss the limitations in cumulating results in controlled 
clinical trials. 
The results of this assessment approach indicate that patients with symp- 
toms of angina who undergo CABGS can expect their chances of becoming 
angina-free to be about 25-40% (see Table 2) greater than if they had remained 
on a medical regimen. The direction of benefit was consistent as the percent 
of patients who were angina-free was always higher in the surgical group for 
the longest follow-up period that was reported. 
The degree of benefit is overestimated by nonrandomized studies that have 
matched medical and surgical patients rather than randomly assigning them 
to treatment. This result replicates previous research cumulating objective 
outcomes [17]. The design effect exceeded conventional levels of significance 
using recently developed parametric methods [22] for calculating common 
and average odds ratio statistics, and it approached significance using a less 
powerful nonparametric test. The chances of a surgical patient remaining 
angina-free were about 15% greater for those in nonrandomized trials com- 
pared to those in RCTs, a 55% increase [(46.2 - 29.8)/29.8]. 
It is also important to identify a potential source of the different findings 
in RCTs and nonrandomized trials. Given the very similar results for medical 
patients in the two types of studies (see Table 1), the design effect is unlikely 
to be due to differences in the distribution of illness severity among medical 
patients or in the way anginal relief was measured. Rather, the design effect 
is most likely attributable to the differences between surgical patients in RCTs 
and nonrandomized studies. 
Accuracy of the Findings 
There is one primary issue that should be examined further in determining 
the accuracy of the quality-of-life measure reported here (the difference be- 
tween the percent of patients in a medical or surgical group that were angina- 
298 P.M. Wortman and W.H. Yeaton 
free), and thus the validity of the estimates found by averaging across studies. 
The sometimes substantial incidence of crossovers from the medical to the 
surgical group in RCTs must be considered. Given that crossovers are typically 
patients with the worst prognosis suffering from rather severe angina [24], 
it is unlikely that the percent of patients who remained angina-free would be 
altered in either group. In addition, because medical patients were often 
dropped from the analysis by the authors of the original studies at the time 
they crossed over, the number of patients who are angina-free would remain 
the same. Neither the numerator, the number of patients who were angina- 
free, nor the denominator, the total number of patients who were assigned 
to a particular group, would likely be influenced under any of these condi- 
tions. 1 
Design Effect 
In the same way that factors having potential impact on the accuracy of 
quality-of-life measures should be examined, so too should those factors that 
may contribute to the existence of a design effect. First, any difference in the 
rate of crossovers between RCTs and nonrandomized trials is unlikely to have 
influenced the difference in estimates found in the two kinds of designs. The 
reason is identical to that discussed above in relation to crossovers and the 
accuracy of the overall difference between life quality in surgical and medical 
groups, namely that crossovers are very likely to be suffering from severe 
angina and, therefore, are unlikely to influence the numerator of the statistic 
used in this research--the number of angina-free patients. Similarly, the de- 
nominator of the statistic used would not be influenced because only a small 
percent of surgical crossovers see point 3, below--were  excluded from the 
calculations. 
Second, because one can expect the recurrence of angina in surgical patients 
as vessels become occluded again [25], it is possible that a difference in average 
follow-up periods between RCTs and nonrandomized trials (see Table 1) might 
explain some of the discrepancy in results. Thus, it is important to determine 
the comparability of follow-up periods in RCTs and nonrandomized trials. A 
much shorter average follow-up period in nonrandomized trials would argue 
against the role of design in producing differential benefit sizes. The average 
follow-up period is only 7 months shorter in nonrandomized trials compared 
to RCTs (i.e., 27 vs. 34 months, respectively). Given average follow-ups in 
RCTs and nonrandomized trials of considerable duration (between 2 and 3 
years), this 7 month difference is not likely to be of sufficient magnitude to 
explain the design effect found in this synthesis. 
1A second, less critical issue related to the specific definition of percent angina-free used in 
this study. Because the denominator used to calculate the percent of angina-free patients was 
based on the total sample (excepting surgical patients who did not receive CABGS) and not the 
reduced sample after deaths have been removed, the percent of patients who were angina-free 
in surgical and medical groups was recalculated and averaged using the number  of angina-free 
patients in the numerator but only the number  of survivors in the denominator. This alternative 
procedure produced results of similar magnitude that led to conclusions identical to those made 
when the total sample was used in the denominator. 
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Third, the decision to slightly alter the commonly recommended intention- 
to-treat principle (patients in the surgical group who did not receive surgery 
were excluded) [26] could potentially have altered results. However,  only 
3.3% of the surgical patients were excluded for this reason and all but one of 
these patients came from an RCT. Had patients who did not receive CABGS 
been included in the denominator, the estimate of benefits of RCTs would 
have decreased. Thus, the procedure used above may slightly understate the 
magnitude of the design effect. 
Finally, differences in illness severity between medical and surgical patients 
and between RCTs and nonrandomized trials might have contributed to the 
design effect. For example, if one makes the common assumption that patients 
with triple-vessel disease are more ill and have more angina, then differential 
selection of patients into either medical or surgical treatments in the studies 
could bias the results. More of such patients in the medical than in the surgical 
group would overestimate the effect while an underestimate of the effect 
would be found with more triple-vessel patients in the surgical than medical 
group. For five of the six RCTs in which this information was provided, there 
were 7.0% more patients with triple-vessel disease in the surgical than medical 
group (47.4% vs. 40.4%). On the other hand, for the three (of eight) nonran- 
domized trials that reported this information there were 7.3% more patients 
with triple-vessel disease in the medical than surgical group (60.3% vs. 53.0%). 
Thus the pattern of this proxy of disease severity suggests that differential 
patient selection may account for some portion of the design effect. 
Selection bias in assigning patients to surgery appears to be the most 
probable explanation of the design effect found between randomized and 
nonrandomized clinical trials. Apparently, research that attempts to match 
groups on their incidence of clinical problems and personal characteristics 
does not adequately equate groups and thus does not rule out initial differ- 
ences as an explanation of outcome. For example, in nonrandomized trials, 
surgical patients and physicians probably played a more active role in choos- 
ing the treatment and may thus have been more committed to perceiving it 
as beneficial while the medical patients were too ill to be considered good 
risks for surgeD,. 
Reporting Quality 
The validity of these cumulated results depends on the quality of infor- 
mation provided in the original published reports. Recently, there has been 
some discussion indicating that important information is often unreported 
[27-29]. The present study was also limited by the information available. There 
were a number of questions that could not be answered due to the lack of 
adequately reported information. 
One question that could not be addressed concerned the conditions under 
which the presence of angina was determined. Good research practice would 
require that those staff who question patients about the extent of their angina 
be unaware of the treatment each patient received. While this requirement 
may be difficult to implement, the absence of information in the original 
studies pertaining to these conditions (only three of the 14 studies described 
assessment conditions) makes this determination problematic. 
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It is also possible that patient and physician expectations regarding poten- 
tial benefits accounted for some unknown portion of the effect attributable 
to surgery. Such placebo effects ("any effect attributable to a pill, potion, or 
procedure but not to its pharmocodynamic or specific properties" [30]) are 
particularly bothersome when subjective measures are involved. The studies 
assessing CABGS did not include a placebo control group because such a 
procedure is considered unethical. Consequently, it is not possible to derive 
a firm estimate for the placebo effect. However,  one may examine other, 
similar treatments to obtain a rough estimate. For example, Beecher [31] noted 
that placebos accounted on average for 35% of "satisfactory relief" in well- 
controlled studies of a variety of medical interventions. In particular, he claimed 
that the placebo effect for surgical relief of angina derived from a subset of 
these studies dealing with internal mammary artery ligafion--a now aban- 
doned procedure--was equal to a 28% difference in "complete pain relief." 
This is almost identical to the effect found for the CABGS RCTs. This effect 
is also comparable to the placebo effect reported for psychotherapy [32]. Thus, 
it is possible that the beneficial effect of CABGS on anginal relief could be 
due to placebo although its duration of 2 to 3 years makes it less plausible 
that it accounts for the entire effect found. 
Another question concerns the amount of relief from angina due to CABGS. 
In nine of 14 studies measures taken at entry indicated that all surgical and 
medical patients displayed symptoms of angina. A small percent of patients 
in the five remaining studies was angina-free at baseline, and this percent 
was typically greater (between 2 and 16%) in the medical group. To gauge 
the effect of this entry difference, one would need to know whether surgical 
or medical treatment is more or less likely to sustain the status of patients 
who are already angina-free. Because data on individual patients were not 
available in each study of this synthesis, it was not possible to determine if 
the entry difference tends to enhance or diminish the benefit of surgery. In 
any event, the small difference in entry rates would argue that overall results 
should be minimally affected. 
One other problem in examining a medical technology over a period of 
time is the changes that occur. Wagner [33] has called this "the moving target 
problem." In the present case there have been major advances in both surgical 
technique and medical practice. A recent report [34] indicates substantial long- 
term benefit can now be achieved using comprehensive medical therapy in- 
cluding beta blockers, nitrates, and nitroglycerin. Thus, the present synthesis 
may overestimate the benefits of CABGS compared to the most recent medical 
interventions in eliminating the angina associated with coronary heart disease. 
Again, it is not possible to assess this because the medical treatment actually 
received by patients was not reported in any of the studies. 
There were numerous other difficulties encountered in conducting this 
research due to poor reporting quality. For example, the actual percentages 
of anginal relief for the CASS report were not mentioned in the text of the 
article, but had to be estimated from a figure. Similarly, in the Berk et al. 
study (see Appendix), information on patients' outcomes and length of follow- 
up had to be calculated from a table. It was also not possible to report symptom 
relief in important subgroups (e.g., one, two, and three vessel disease pa- 
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tients) because these results were not consistently provided in the original 
studies. 
Though the cumulation of study results is necessarily imperfect due to 
inconsistencies in publication standards, quality of individual studies, and 
unresolved problems with outcome measures, the approach offers the dual 
advantages of timeliness and cost-effectiveness. Cumulative results of existing 
controlled clinical trials can be produced in a much shorter time and at greatly 
reduced expense when compared to results from a new, multicenter clinical 
trial. In fact, as illustrated by Chalmers and his colleagues [14], the cumulative 
results may indicate no further need for a controlled trial [14]. 
Further research should focus on other quality of life measures besides 
freedom from angina. The measurement of quality of life is difficult and some 
measures are particularly troublesome. For example, a follow-up consensus 
conference on CABGS regarded postoperative employment status as an in- 
appropriate major index of quality of life [35]. This should not deter medical 
researchers from including appropriate quality-of-life measures, however. As 
Weinstein [36] has noted: 
• . . to omit quality of life and other intangible considerations because of diffi- 
culties in measurement would be irresponsible if these considerations are central 
to the concerns of the physician, the patient, and the collection of patients and 
potential patients we call society (p. 311). 
Thus, accurate estimates of the relative, subjective benefit of CABGS are 
vital to informed decisions by individual physicians and patients to recom- 
mend and accept surgery. In addition, these estimates are likely to be included 
in more comprehensive technology assessments. To illustrate, Weinstein and 
Stason [37] utilized data on degree of symptom relief to estimate the quality- 
adjusted life expectancy and cost effectiveness of both CABGS and medical 
treatments. Unfortunately, the medical group data were taken at 2-year fol- 
low-up and the surgical group data at 1- and 7-year follow-up in three different 
studies• Such methodological inconsistencies greatly diminish the validity of 
any subsequent estimates and indicate clearly the potential need for quality- 
of-life measures accurately synthesized from previous research. 
In summary, the results of this research indicate that those patients who 
suffer from angina and subsequently receive CABGS are more likely to become 
angina-free than patients who are treated medically. Estimates of the likeli- 
hood of becoming angina-free are approximately 40% greater in the surgical 
than the medical group• When estimates are based solely on results in RCTs, 
the degree of benefit is reduced by approximately 10%. These basic findings 
remain intact when one uses alternative estimates of the percent of patients 
who are angina-free. Finally, replication of the design effect found in a larger 
set of studies using a different outcome measure further establishes its im- 
portance in the generation of accurate estimates of benefit• 
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APPENDIX 
Articles used  in data synthesis:  
RCTs 
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